

Francesco Ernesto Pontieri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6555783/publications.pdf>

Version: 2024-02-01

113
papers

7,644
citations

117625

34
h-index

53230

85
g-index

116
all docs

116
docs citations

116
times ranked

7668
citing authors

#	ARTICLE	IF	CITATIONS
1	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1641-1649.	3.9	1,171
2	Cannabinoid and Heroin Activation of Mesolimbic Dopamine Transmission by a Common μ Opioid Receptor Mechanism. <i>Science</i> , 1997, 276, 2048-2050.	12.6	1,059
3	Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. <i>Nature</i> , 1996, 382, 255-257.	27.8	1,015
4	Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 12304-12308.	7.1	783
5	Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. <i>Brain</i> , 2010, 133, 3423-3433.	7.6	374
6	Drug Addiction as a Disorder of Associative Learning: Role of Nucleus Accumbens Shell/Extended Amygdala Dopamine. <i>Annals of the New York Academy of Sciences</i> , 1999, 877, 461-485.	3.8	204
7	The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. <i>Journal of Neurology</i> , 2012, 259, 2621-2631.	3.6	188
8	Contribution of Blockade of the Noradrenaline Carrier to the Increase of Extracellular Dopamine in the Rat Prefrontal Cortex by Amphetamine and Cocaine. <i>European Journal of Neuroscience</i> , 1997, 9, 2077-2085.	2.6	153
9	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , 2010, 257, 5-14.	3.6	140
10	The recognition of facial emotion expressions in Parkinson's disease. <i>European Neuropsychopharmacology</i> , 2008, 18, 835-848.	0.7	97
11	Supine hypertension in Parkinson's disease and multiple system atrophy. <i>Clinical Autonomic Research</i> , 2016, 26, 97-105.	2.5	87
12	Neuropharmacology and behavior in planarians: Translations to mammals. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2008, 147, 399-408.	2.6	84
13	Prodromal non-motor symptoms of Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 145-151.	2.2	83
14	Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 76-82.	1.9	82
15	Behavioral sensitization to heroin by cannabinoid pretreatment in the rat. <i>European Journal of Pharmacology</i> , 2001, 421, R1-R3.	3.5	80
16	The Dopaminergic System in Peripheral Blood Lymphocytes: From Physiology to Pharmacology and Potential Applications to Neuropsychiatric Disorders. <i>Current Neuropharmacology</i> , 2011, 9, 278-288.	2.9	76
17	Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2001, 108, 803-807.	2.8	65
18	The potential prognostic role of cardiovascular autonomic failure in α -synucleinopathies. <i>European Journal of Neurology</i> , 2013, 20, 231-235.	3.3	61

#	ARTICLE	IF	CITATIONS
19	Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease. <i>NeuroReport</i> , 1999, 10, 2907-2910.	1.2	58
20	Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study. <i>Journal of Neurology</i> , 2018, 265, 1124-1137.	3.6	52
21	Intensity-dependent facial emotion recognition and cognitive functions in Parkinson's disease. <i>Journal of the International Neuropsychological Society</i> , 2010, 16, 867-876.	1.8	49
22	Metabolic mapping of the effects of intravenous methamphetamine administration in freely moving rats. <i>Psychopharmacology</i> , 1990, 102, 175-182.	3.1	47
23	Amyotrophic lateral sclerosis and sports: a case-control study. <i>European Journal of Neurology</i> , 2005, 12, 223-225.	3.3	47
24	Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. <i>Journal of Neurology</i> , 2014, 261, 1291-1299.	3.6	47
25	Psychostimulant drugs increase glucose utilization in the shell of the rat nucleus accumbens. <i>NeuroReport</i> , 1994, 5, 2561-2564.	1.2	46
26	Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study. <i>Journal of Neurology</i> , 1996, 243, 422-425.	3.6	44
27	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 90-92.	2.2	44
28	Acetylcholine/dopamine interaction in planaria. <i>Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology</i> , 2000, 125, 225-231.	0.5	40
29	Minocycline in amyotrophic lateral sclerosis: a pilot study. <i>Neurological Sciences</i> , 2005, 26, 285-287.	1.9	39
30	An exploratory case-control study on spinal and bulbar forms of amyotrophic lateral sclerosis in the province of Rome. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 361-369.	2.1	39
31	Alexithymia Is a Non-Motor Symptom of Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 133-141.	1.2	38
32	Blood Dendritic Cell Frequency Declines in Idiopathic Parkinson's Disease and Is Associated with Motor Symptom Severity. <i>PLoS ONE</i> , 2013, 8, e65352.	2.5	38
33	Foot Pressure Wearable Sensors for Freezing of Gait Detection in Parkinson's Disease. <i>Sensors</i> , 2021, 21, 128.	3.8	38
34	Neuropsychiatric and cognitive symptoms and body side of onset of parkinsonism in unmedicated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1096-1100.	2.2	36
35	Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson's disease. <i>European Neuropsychopharmacology</i> , 2015, 25, 69-76.	0.7	35
36	Opioid-dopamine interaction in planaria: a behavioral study. <i>Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology</i> , 1999, 124, 51-55.	0.5	34

#	ARTICLE	IF	CITATIONS
37	Adrenal dysregulation in amyotrophic lateral sclerosis. <i>Journal of Endocrinological Investigation</i> , 2003, 26, RC23-RC25.	3.3	34
38	Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor. <i>Journal of Neural Transmission</i> , 2007, 114, 935-938.	2.8	34
39	Dopamine receptor mRNAs in the rat lymphocytes. <i>Life Sciences</i> , 1998, 62, 1919-1925.	4.3	33
40	Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1393-1397.	2.2	33
41	Application of the 5-2-1™ screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. <i>Neurodegenerative Disease Management</i> , 2020, 10, 309-323.	2.2	33
42	Behavioral sensitization to WIN55212.2 in rats pretreated with heroin. <i>Brain Research</i> , 2001, 898, 178-180.	2.2	32
43	Anosognosia for cognitive and behavioral symptoms in Parkinson's disease with mild dementia and mild cognitive impairment: Frequency and neuropsychological/neuropsychiatric correlates. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 62-67.	2.2	32
44	Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 50-56.	2.2	31
45	Drug Choices and Advancements for Managing Depression in Parkinson's Disease. <i>Current Neuropharmacology</i> , 2020, 18, 277-287.	2.9	31
46	Local cerebral glucose utilization after D1 receptor stimulation in 6-OHDA lesioned rats: Effect of sensitization (priming) with a dopaminergic agonist. <i>Synapse</i> , 1993, 13, 264-269.	1.2	30
47	Metabolic Mapping of the Effects of Win 55212's Intravenous Administration in the Rat. <i>Neuropsychopharmacology</i> , 1999, 21, 773-776.	5.4	29
48	Intravenous morphine increases glucose utilization in the shell of the rat nucleus accumbens. <i>European Journal of Pharmacology</i> , 1996, 302, 49-51.	3.5	26
49	Heroin sensitization as mapped by c-Fos immunoreactivity in the rat striatum. <i>Brain Research</i> , 2002, 933, 144-149.	2.2	26
50	Regional cortical thickness and cognitive functions in non-demented Parkinson's disease patients: a pilot study. <i>European Journal of Neurology</i> , 2012, 19, 172-175.	3.3	26
51	Functional correlates of nicotine administration: similarity with drugs of abuse. <i>Journal of Molecular Medicine</i> , 1998, 76, 193-201.	3.9	25
52	Dopamine transporter immunoreactivity in peripheral blood mononuclear cells in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2006, 13, 416-418.	3.3	25
53	Cannabinoid-induced stimulation of motor activity in planaria through an opioid receptor-mediated mechanism. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 65-68.	4.8	23
54	Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 871-875.	2.2	23

#	ARTICLE	IF	CITATIONS
55	<sc>DUOGLOBE</sc>: One-Year Outcomes in a <sc>Real-World</sc> Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1061-1074.	1.5	22
56	Early distinction of Parkinsonian variant multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 440-441.	3.9	21
57	Functional correlates of heroin sensitization in the rat brain. <i>European Journal of Pharmacology</i> , 1997, 335, 133-137.	3.5	19
58	Central and peripheral dopamine transporter reduction in Parkinson's disease. <i>Neurological Research</i> , 2009, 31, 687-691.	1.3	19
59	Urinary retention discriminates multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1926-1928.	3.9	19
60	Alpha-synuclein in salivary gland as biomarker for Parkinsonian disease. <i>Reviews in the Neurosciences</i> , 2019, 30, 455-462.	2.9	19
61	Safinamide improves executive functions in fluctuating Parkinsonian disease patients: an exploratory study. <i>Journal of Neural Transmission</i> , 2021, 128, 273-277.	2.8	19
62	Functional correlates of repeated administration of cocaine and apomorphine in the rat. <i>European Journal of Pharmacology</i> , 1995, 284, 205-209.	3.5	18
63	Differential effects of acute administration of clozapine or haloperidol on local cerebral glucose utilization in the rat. This study was partially supported by the Italian Health Department. <i>Brain Research</i> , 1997, 768, 273-278.	2.2	18
64	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. <i>Neurological Sciences</i> , 2012, 33, 585-593.	1.9	18
65	Changes in neuropeptide FF and NPY immunohistochemical patterns in rat brain under heroin treatment. <i>Brain Research</i> , 2006, 1083, 151-158.	2.2	17
66	Increased Lymphocyte Dopamine β -Hydroxylase Immunoreactivity in Alzheimerian Disease: Compensatory Response to Cholinergic Deficit?. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 18, 338-341.	1.5	15
67	The early course of affective and cognitive symptoms in de novo patients with Parkinsonian disease. <i>Journal of Neurology</i> , 2014, 261, 1126-1132.	3.6	14
68	Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2009, 116, 161-165.	2.8	13
69	Hemiparkinsonism due to frontal meningioma. <i>Acta Neurologica Belgica</i> , 2008, 108, 29-32.	1.1	13
70	The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinsonian disease: an observational study. <i>European Journal of Medical Research</i> , 2013, 18, 60.	2.2	12
71	HEDONIC TONE AND ITS MOOD AND COGNITIVE CORRELATES IN PARKINSON'S DISEASE. <i>Depression and Anxiety</i> , 2013, 30, 85-91.	4.1	11
72	Phosphorylated β -synuclein immunoreactivity in nerve fibers from minor salivary glands in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 99-101.	2.2	11

#	ARTICLE	IF	CITATIONS
73	Action Observation With Dual Task for Improving Cognitive Abilities in Parkinson's Disease: A Pilot Study. <i>Frontiers in Systems Neuroscience</i> , 2019, 13, 7.	2.5	11
74	Metabolic mapping of the synergism between MK-801 and SKF 38393 in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. <i>Synapse</i> , 1992, 12, 255-260.	1.2	10
75	Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 355-357.	3.9	10
76	Botulinum toxin type A for Holmes tremor secondary to thalamic hemorrhage. <i>Neurological Sciences</i> , 2015, 36, 1935-1936.	1.9	10
77	Orthostatic hypotension acutely impairs executive functions in Parkinson's disease. <i>Neurological Sciences</i> , 2018, 39, 1459-1462.	1.9	10
78	Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study. <i>Neurological Sciences</i> , 2018, 39, 141-143.	1.9	10
79	Treatment with 6-hydroxydopamine in planaria (<i>Dugesia gonocephala</i> s.l.): morphological and behavioral study. <i>Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology</i> , 1999, 123, 201-207.	0.5	9
80	Rotigotine for anxiety during wearing-off in Parkinson's disease with dementia. <i>Aging Clinical and Experimental Research</i> , 2013, 25, 601-603.	2.9	9
81	Gender specific decrease of a set of circulating N-acylphosphatidyl ethanolamines (NAPEs) in the plasma of Parkinson's disease patients. <i>Metabolomics</i> , 2019, 15, 74.	3.0	9
82	Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism. <i>Brain and Behavior</i> , 2019, 9, e01448.	2.2	9
83	<p></p>Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 2899-2912.	2.2	9
84	Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease. <i>Journal of Personalized Medicine</i> , 2021, 11, 51.	2.5	9
85	Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study. <i>Neurological Research</i> , 2021, 43, 950-954.	1.3	9
86	Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel. <i>Journal of Parkinson's Disease</i> , 2022, 12, 917-926.	2.8	9
87	Alterations in opiate receptor binding in MPTP-induced hemiparkinsonian monkeys. <i>Neuroscience Letters</i> , 1991, 127, 155-159.	2.1	8
88	Depressive symptoms in Parkinson's disease and in non-neurological medical illnesses. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 389.	2.2	8
89	Treatment with botulinum toxin for anti-MAG neuropathy-related arm tremor. <i>Neurological Sciences</i> , 2015, 36, 333-334.	1.9	8
90	The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2020, 127, 881-891.	2.8	8

#	ARTICLE	IF	CITATIONS
91	Immune System and Neuroinflammation in Idiopathic Parkinson's Disease: Association Analysis of Genetic Variants and miRNAs Interactions. <i>Frontiers in Genetics</i> , 2021, 12, 651971.	2.3	8
92	The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 1689-1692.	2.9	7
93	Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study. <i>Neurological Research</i> , 2009, 31, 74-76.	1.3	6
94	Dopaminergic system in peripheral blood mononuclear cells in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 125-126.	3.9	6
95	Neuropharmacology of Cannabinoid System: From Basic Science to Clinical Applications. <i>Current Neuropharmacology</i> , 2004, 2, 1-7.	2.9	6
96	Cerebellar GABA Levels and Cognitive Interference in Parkinson's disease and Healthy Comparators. <i>Journal of Personalized Medicine</i> , 2021, 11, 16.	2.5	6
97	Increased motor response to cocaine administration following recovery from chronic corticosterone treatment in the rat. <i>European Neuropsychopharmacology</i> , 1998, 8, 43-46.	0.7	5
98	Effects of intra-VTA injection of neurotensin on local cerebral glucose utilization in freely moving rats. <i>Peptides</i> , 2000, 21, 1751-1753.	2.4	5
99	Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease. <i>Pharmacological Reports</i> , 2011, 63, 1056-1060.	3.3	4
100	Psychiatric profile of motor subtypes of de novo drug-naïve Parkinson's disease patients. <i>Brain and Behavior</i> , 2018, 8, e01094.	2.2	4
101	Percutaneous endoscopic gastrojejunostomy in pediatric intestinal pseudo-obstruction. <i>Nutrition</i> , 2021, 86, 111174.	2.4	4
102	Selective metabolic activation by apomorphine in striosomes of denervated striatum in MPTP-induced hemiparkinsonian monkeys. <i>NeuroReport</i> , 1995, 6, 1330-1332.	1.2	3
103	Effects of haloperidol on the expression of lymphocyte dopamine receptor mRNAs in the rat. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1999, 23, 851-859.	4.8	3
104	Choline acetyltransferase of the common type immunoreactivity in the rat brain following different heroin treatments: A pilot study. <i>Journal of Chemical Neuroanatomy</i> , 2011, 41, 111-121.	2.1	3
105	Dopamine release in striatal slices of rats previously submitted to electroconvulsive shock. <i>Brain Research</i> , 1997, 774, 239-241.	2.2	2
106	Electroconvulsive shock blocks the opioid-mediated inhibition of dopamine release in rat striatal slices. <i>Journal of Neural Transmission</i> , 1997, 104, 805-810.	2.8	2
107	Unraveling predictors affecting compliance to MRI in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 964-967.	2.2	2
108	Validation of the Canadian Occupational Performance Measure in Italian Parkinson's Disease Clients. <i>Physical and Occupational Therapy in Geriatrics</i> , 2022, 40, 26-37.	0.4	2

#	ARTICLE	IF	CITATIONS
109	Increased functional response to cocaine challenge following recovery from chronic corticosterone in the rat. <i>European Journal of Pharmacology</i> , 1997, 336, 159-162.	3.5	1
110	Effects of the intravenous administration of [Lys7]dermorphin on local cerebral glucose utilization in the rat. <i>European Journal of Pharmacology</i> , 2006, 544, 17-20.	3.5	1
111	On the relationship between side of onset and cognition in Parkinson disease: Response from the authors. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1481-1482.	2.2	1
112	Levodopa/carbidopa intestinal gel for pain related to levodopa-induced motor complications in Parkinson's disease. <i>Neurological Sciences</i> , 2022, , 1.	1.9	1
113	Plasma Exchange-responsive Tardive Delayed Pseudochoreoathetosis in a Patient with Anti-Hu Neuronopathy. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 887-888.	1.5	0